Authors' objectives:

To summarise the current research evidence on teriparatide (Forteo) for osteoporosis.

Authors' recommendations: - Clinical impact: Teriparatide is the first of a new class of drug for the management of osteoporosis-related fractures and because of the size of the patient group may lead to a significant clinical impact. - Service impact: The introduction of teriparatide for osteoporosis is unlikely to cause a significant service impact. Although teriparatide increases the risk of transient hypercalcaemia routine monitoring is not thought to be necessary. - Patient issues: Teriparatide is administered by subcutaneous injection and can be given by the patients themselves. This may limit its acceptability for some people. - Financial and overall NHS impact: Because of its recombinant nature teriparatide may cost significantly more than current treatment options and this combined with the large potential patient group may lead to a significant overall effect.

Authors' methods: Overview

Project Status: Completed

Year Published: 2001

URL for published report: http://www.hsric.nihr.ac.uk/search

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: National Horizon Scanning Centre